

- [1] Werfel T, Heratizadeh A, Aberer W et al. S3 Guideline Atopic dermatitis: Part 1 - General aspects, topical and non-drug therapies, special patient groups. *J Dtsch Dermatol Ges* 2024; 22(1): 137-153.
- [2] Werfel T, Heratizadeh A, Aberer W et al. S3 guideline Atopic dermatitis: Part 2 - Systemic treatment. *J Dtsch Dermatol Ges* 2024; 22(2): 307-320.
- [3] Werfel T, Aberer W, Augustin M et al. [Atopic dermatitis: S2 guidelines]. *J Dtsch Dermatol Ges* 2009; 7 Suppl 1: S1-46.
- [4] Pariser DM, Simpson EL, Gadhari A et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). *Curr Med Res Opin* 2020; 36(3): 367-376.
- [5] Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. *J Am Acad Dermatol* 2006; 54(1): 1-15; quiz 16-18.
- [6] Cury Martins J, Martins C, Aoki V et al. Topical tacrolimus for atopic dermatitis. *Cochrane Database Syst Rev* 2015; 2015(7): CD009864.
- [7] Alaiti S, Kang S, Fiedler VC et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. *J Am Acad Dermatol* 1998; 38(1): 69-76.
- [8] Wollenberg A, Reitamo S, Atzori F et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. *Allergy* 2008; 63(6): 742-750.
- [9] Thaci D, Reitamo S, Gonzalez Ensenat MA et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. *Br J Dermatol* 2008; 159(6): 1348-1356.
- [10] Dahnhardt D, Bastian M, Dahnhardt-Pfeiffer S et al. Comparing the effects of proactive treatment with tacrolimus ointment and mometasone furoate on the epidermal barrier structure and ceramide levels of patients with atopic dermatitis. *J Dermatolog Treat* 2021; 32(7): 721-729.
- [11] Chittock J, Brown K, Cork MJ, Danby SG. Comparing the Effect of a Twice-weekly Tacrolimus and Betamethasone Valerate Dose on the Subclinical Epidermal Barrier Defect in Atopic Dermatitis. *Acta Derm Venereol* 2015; 95(6): 653-658.
- [12] Buchau AS, MacLeod DT, Morizane S et al. Bcl-3 acts as an innate immune modulator by controlling antimicrobial responses in keratinocytes. *J Invest Dermatol* 2009; 129(9): 2148-2155.
- [13] Lambers H, Piessens S, Bloem A et al. Natural skin surface pH is on average below 5, which is beneficial for its resident flora. *Int J Cosmet Sci* 2006; 28(5): 359-370.
- [14] Averbek M, Gebhardt C, Emmrich F et al. Immunologic principles of allergic disease. *J Dtsch Dermatol Ges* 2007; 5(11): 1015-1028.
- [15] Volz T, Kaesler S, Skabytska Y, Biedermann T. [The role of the innate immune system in atopic dermatitis]. *Hautarzt* 2015; 66(2): 90-95.
- [16] Molla A. A Comprehensive Review of Phototherapy in Atopic Dermatitis: Mechanisms, Modalities, and Clinical Efficacy. *Cureus* 2024; 16(3): e56890.
- [17] Heinlin J, Schiffner-Rohe J, Schiffner R et al. A first prospective randomized controlled trial on the efficacy and safety of synchronous balneophototherapy vs. narrow-band UVB monotherapy for atopic dermatitis. *J Eur Acad Dermatol Venereol* 2011; 25(7): 765-773.
- [18] Hoffmann VH, J.: Aktiv kontrollierte, randomisierte, multizentrische Phase III Studie zum Nachweis des Zusatznutzens der synchronen Balneo-Phototherapie bei Patienten mit atopischem Ekzem (Neurodermitis). In: Bundesausschusses UMDg, ed. Abschlussbericht Beratungsverfahren gemäß § 135 Absatz 1 Satz 1 SGB V Balneophototherapie bei atopischem Ekzem 2020.
- [19] von Kobyletzki G, Freitag M, Herde M et al. [Phototherapy in severe atopic dermatitis. Comparison between current UVA1 therapy, UVA1 cold light and combined UVA-UVB therapy]. *Hautarzt* 1999; 50(1): 27-33.
- [20] Krutmann J, Czech W, Diepgen T et al. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. *J Am Acad Dermatol* 1992; 26(2 Pt 1): 225-230.
- [21] Silverberg JI, Bunick CG, Hong HC et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up). *Br J Dermatol* 2024.
- [22] Hasan I, Parsons L, Duran S, Zinn Z. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study. *J Am Acad Dermatol* 2024; 91(2): 255-258.
- [23] Castellsague J, Kuiper JG, Pottegard A et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). *Clin Epidemiol* 2018; 10: 299-310.
- [24] Kook H, Gwag HE, Park SY et al. Detecting T-cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab. *J Eur Acad Dermatol Venereol* 2024; 38(10): 1939-1946.
- [25] Mazzetto R, Miceli P, Tartaglia J et al. Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma. *Life (Basel)* 2024; 14(2).
- [26] Kridin K, Ludwig RJ. Response to Hasan et al, "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study". *J Am Acad Dermatol* 2024.
- [27] Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. *J Eur Acad Dermatol Venereol* 2018; 32(6): 850-878.
- [28] Weischer M, Rocken M, Bernburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? *Exp Dermatol* 2007; 16(5): 385-393.
- [29] Reich K, Thyssen JP, Blauvelt A et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized, double-blind, multicentre phase 3 trial. *Lancet* 2022; 400(10348): 273-282.
- [30] Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. *Allergy* 2020; 75(1): 54-62.
- [31] Blauvelt A, Simpson EL, Tying SK et al. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. *J Am Acad Dermatol* 2019; 80(1): 158-167 e151.

- [32] Davis JD, Bansal A, Hassman D et al. Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab. *Clin Pharmacol Ther* 2018; 104(6): 1146-1154.
- [33] Wollenberg A, Beck LA, Blauvelt A et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). *Br J Dermatol* 2020; 182(5): 1120-1135.
- [34] Fachinfo. Fachinformation Dupixent. <https://www.fachinfo.de/fi/detail/021745/dupixent-r-300-mg-injektionsloesung-in-einer-fertigspritze-dupixent-r-300-mg-injektionsloesung-im-fertigen>: Fachinfo.de; 2024.
- [35] Maurer M, Casale TB, Saini SS et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. *J Allergy Clin Immunol* 2024; 154(1): 184-194.
- [36] Maurer M, Casale TB, Saini SS et al. Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels. *Dermatol Ther (Heidelb)* 2024; 14(9): 2427-2441.
- [37] Silverberg JI, Yosipovitch G, Simpson EL et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. *J Am Acad Dermatol* 2020; 82(6): 1328-1336.
- [38] Simpson EL, Bieber T, Guttman-Yassky E et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N Engl J Med* 2016; 375(24): 2335-2348.
- [39] Silverberg JI, Guttman-Yassky E, Thaci D et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. *N Engl J Med* 2023; 388(12): 1080-1091.
- [40] Blauvelt A, Thyssen JP, Guttman-Yassky E et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. *Br J Dermatol* 2023; 188(6): 740-748.
- [41] Silverberg JI, Wollenberg A, Reich A et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. *Lancet* 2024; 404(10451): 445-460.
- [42] EMA. Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Nemluvio, intended for the treatment of atopic dermatitis and prurigo nodularis. <https://www.ema.europa.eu/en/medicines/human/EPAR/nemluvio>; 2024.
- [43] Wollenberg A, Blauvelt A, Guttman-Yassky E et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). *Br J Dermatol* 2021; 184(3): 437-449.
- [44] Silverberg JI, Toth D, Bieber T et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. *Br J Dermatol* 2021; 184(3): 450-463.
- [45] Blauvelt A, Langley RG, Lacour JP et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. *J Am Acad Dermatol* 2022; 87(4): 815-824.
- [46] Croft M, Esfandiari E, Chong C et al. OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. *Am J Clin Dermatol* 2024; 25(3): 447-461.
- [47] Weidinger S, Bieber T, Cork MJ et al. Safety and efficacy of amltelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. *Br J Dermatol* 2023; 189(5): 531-539.
- [48] Guttman-Yassky E, Simpson EL, Reich K et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. *Lancet* 2023; 401(10372): 204-214.
- [49] Rewerska B, Sher LD, Alpizar S et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis. *J Allergy Clin Immunol Glob* 2024; 3(1): 100195.
- [50] Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. *J Allergy Clin Immunol* 2021; 148(4): 927-940.
- [51] Gooderham MJ, Forman SB, Bissonnette R et al. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. *JAMA Dermatol* 2019; 155(12): 1371-1379.
- [52] Simpson EL, Sinclair R, Forman S et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet* 2020; 396(10246): 255-266.
- [53] Reich K, Silverberg JI, Papp KA et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. *J Eur Acad Dermatol Venereol* 2023; 37(10): 2056-2066.
- [54] Eichenfield LF, Flohr C, Sidbury R et al. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. *JAMA Dermatol* 2021; 157(10): 1165-1173.
- [55] Simpson EL, Silverberg JI, Nosbaum A et al. Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure. *Am J Clin Dermatol* 2024; 25(4): 639-654.
- [56] Simpson EL, Lacour JP, Spelman L et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. *Br J Dermatol* 2020; 183(2): 242-255.
- [57] Torrelo A, Rewerska B, Galimberti M et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). *Br J Dermatol* 2023; 189(1): 23-32.

- [58] Bieber T, Reich K, Paul C et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). *Br J Dermatol* 2022; 187(3): 338-352.
- [59] Guttman-Yassky E, Teixeira HD, Simpson EL et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. *Lancet* 2021; 397(10290): 2151-2168.
- [60] Silverberg JI, de Bruin-Weller M, Bieber T et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. *J Allergy Clin Immunol* 2022; 149(3): 977-987 e914.
- [61] Burmester GR, Cohen SB, Winthrop KL et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. *RMD Open* 2023; 9(1).
- [62] Werfel T, Heratizadeh A, Aberer W et al. S2k guideline on diagnosis and treatment of atopic dermatitis - short version. *Allergo J Int* 2016; 25: 82-95.
- [63] EMA. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 2024. <https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders>; 2022.
- [64] Simpson E, Eckert L, Gadkari A et al. Validation of the Atopic Dermatitis Control Tool (ADCT(c)) using a longitudinal survey of biologic-treated patients with atopic dermatitis. *BMC Dermatol* 2019; 19(1): 15.
- [65] Hebert AA, Flohr C, Hong HC et al. Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials. *J Dermatolog Treat* 2024; 35(1): 2324833.
- [66] Blauvelt A, Guttman-Yassky E, Paller AS et al. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). *Am J Clin Dermatol* 2022; 23(3): 365-383.
- [67] Paller AS, Flohr C, Cork M et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. *JAMA Dermatol* 2023; 159(6): 596-605.
- [68] Paller AS, Ladizinski B, Mendes-Bastos P et al. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. *JAMA Dermatol* 2023; 159(5): 526-535.
- [69] Worm M, Reese I, Ballmer-Weber B et al. Guidelines on the management of IgE-mediated food allergies: S2k-Guidelines of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Medical Association of Allergologists (AeDA), the German Professional Association of Pediatricians (BVKJ), the German Allergy and Asthma Association (DAAB), German Dermatological Society (DDG), the German Society for Nutrition (DGE), the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS), the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery, the German Society for Pediatric and Adolescent Medicine (DGKJ), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Society for Pneumology (DGP), the German Society for Pediatric Gastroenterology and Nutrition (GPGE), German Contact Allergy Group (DKG), the Austrian Society for Allergology and Immunology (AE-GAI), German Professional Association of Nutritional Sciences (VDOE) and the Association of the Scientific Medical Societies Germany (AWMF). *Allergo J Int* 2015; 24: 256-293.
- [70] Jakasa I, Thyssen JP, Kezic S. The role of skin barrier in occupational contact dermatitis. *Exp Dermatol* 2018; 27(8): 909-914.
- [71] Thyssen JP, Thuesen B, Huth C et al. Skin barrier abnormality caused by filaggrin (FLG) mutations is associated with increased serum 25-hydroxyvitamin D concentrations. *J Allergy Clin Immunol* 2012; 130(5): 1204-1207 e1202.
- [72] Agner T, Elsner P. Sodium lauryl sulfate: a never ending story? *Br J Dermatol* 2020; 183(1): 13.
- [73] Bauer A, Brans R, Brehler R et al. [S2k-Leitlinie Diagnostik, Prävention und Therapie des Handekzems: S2k guideline diagnosis, prevention and therapy of hand eczema]. *J Dtsch Dermatol Ges* 2023; 21(9): 1054-1076.
- [74] Loman L, Brands MJ, Massella Patsea AAL et al. Lifestyle factors and hand eczema: A systematic review and meta-analysis of observational studies. *Contact Dermatitis* 2022; 87(3): 211-232.
- [75] Anveden Berglind I, Alderling M, Meding B. Life-style factors and hand eczema. *Br J Dermatol* 2011; 165(3): 568-575.
- [76] Bissonnette R, Warren RB, Pinter A et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. *Lancet* 2024; 404(10451): 461-473.
- [77] Fowler JF, Graff O, Hamedani AG. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. *J Drugs Dermatol* 2014; 13(10): 1198-1204.
- [78] Schmith GD, Singh R, Gomeni R et al. Use of Longitudinal Dose-Response Modeling to Support the Efficacy and Tolerability of Alitretinoin in Severe Refractory Chronic Hand Eczema (CHE). *CPT Pharmacometrics Syst Pharmacol* 2015; 4(4): 255-262.
- [79] Morris M, Schifano L, Fong R, Graff O. Safety of alitretinoin for severe refractory chronic hand eczema: Clinical studies and postmarketing surveillance. *J Dermatolog Treat* 2016; 27(1): 54-58.
- [80] Simpson EL, Silverberg JI, Worm M et al. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. *J Am Acad Dermatol* 2024; 90(6): 1190-1199.
- [81] Bauer A, Brans R, Brehler R et al. S2k guideline diagnosis, prevention, and therapy of hand eczema. *J Dtsch Dermatol Ges* 2023; 21(9): 1054-1074.

[82] Blauvelt A, Teixeira HD, Simpson EL et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. *JAMA Dermatol* 2021; 157(9): 1047-1055.

[83] Blauvelt A, Ladizinski B, Prajapati VH et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). *J Am Acad Dermatol* 2023; 89(3): 478-485.

[84] Bohner A, Jargosch M, Muller NS et al. The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant T(H)2/T(H)17 immune response. *J Allergy Clin Immunol* 2023; 152(2): 408-419.

[85] Patruno C, Stingeni L, Hansel K et al. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults. *Dermatol Ther* 2020; 33(3): e13290.

[86] Thunemann J, Muller S, Steinbrink K et al. Chronic Prurigo. *J Dtsch Dermatol Ges* 2024; 22(6): 813-823.

[87] Kwatra SG, Stander S, Yosipovitch G et al. Pathophysiology of Prurigo Nodularis: Neuroimmune Dysregulation and the Role of Type 2 Inflammation. *J Invest Dermatol* 2024.

[88] Yosipovitch G, Kim BS, Kwatra SG et al. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2). *JAAD Int* 2024; 16: 163-174.

[89] Kwatra SG, Yosipovitch G, Legat FJ et al. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. *N Engl J Med* 2023; 389(17): 1579-1589.

onkoderm e.V.

Das bundesweite Netzwerk wurde Ende 2009 von Dermato-Onkologen gegründet, zunächst mit dem Anspruch, neueste Erkenntnisse zum Thema Hautkrebs zu vermitteln und in die niedergelassene Praxis zu tragen. Übergreifendes Ziel von onkoderm ist es aber auch, die Dermatologie als integralen Bestandteil der Gesamtmedizin zu stärken und somit das Image des Gesamtfaches Dermatologie durch hochwertige, nachhaltige und fachlich kompetente Qualität in der Versorgung zu optimieren. Folgerichtig hat sich das Netzwerk weiterentwickelt vom anfänglichen Fokus auf die Hautkrebs-Therapie hin zur Systemtherapie dermatologischer Erkrankungen und zur Entwicklung praxisnaher Werkzeuge zur Verbesserung der Versorgungssituation in Deutschland.

onkoderm[®]

Praktische Dermatologie mit System www.onkoderm.de

IMPRESSUM

Herausgeber, Copyright und verantwortlich für den Inhalt:

onkoderm e.V. Geschäftsstelle

Leiter: Klaus M. Hartgens

Am Hauptbahnhof 6 · 53111 Bonn

Fon: 0228-50443280

office@onkoderm.de

www.onkoderm.de

Verantwortlich im Sinne des Presserechts:

Prof. Dr. med. Hjalmar Kurzen

c/o onkoderm e.V.

Am Hauptbahnhof 6 · 53111 Bonn

Fon: 0228-50443280

office@onkoderm.de

Mit freundlicher Unterstützung von:

AbbVie Deutschland GmbH & Co. KG,

Almirall Hermal GmbH,

Galderma Laboratorium GmbH,

LEO Pharma GmbH,

Lilly Deutschland GmbH,

Pfizer Pharma GmbH,

Sanofi-Aventis Deutschland GmbH